BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum

Reuters01-12

BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum

Jan 12 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:

MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUM
MIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCE
MIRUM PHARMACEUTICALS INC - 2026 EXPECTED GLOBAL NET PRODUCT SALES OF $630 MILLION TO $650 MILLION
MIRUM PHARMACEUTICALS INC - VOLIXIBAT VISTAS STUDY IN PRIMARY SCLEROSING CHOLANGITIS $(PSC)$ TOPLINE DATA EXPECTED Q2 2026
MIRUM PHARMACEUTICALS INC - LIVMARLI EXPAND STUDY IN ADDITIONAL CHOLESTATIC PRURITUS SETTINGS TIMING ACCELERATED; TOPLINE DATA NOW EXPECTED Q4 2026
MIRUM PHARMACEUTICALS - BLUEJAY THERAPEUTICS' AZURE-1 STUDY IN HDV INTERIM DATA EXPECTED IN Q2 2026, TOPLINE PHASE 3 DATA EXPECTED IN H2 2026

Source text: ID:nBw9vnK6qa

Further company coverage: MIRM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602754849?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602754849","market":"nz","top_or_hot":-1,"title":"BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Mirum Pharmaceuticals Inc <span>MIRM.O</span>:</p><ul><li><p>MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUM</p></li><li><p>MIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCE</p></li><li><p>MIRUM PHARMACEUTICALS INC - 2026 EXPECTED GLOBAL NET PRODUCT SALES OF $630 MILLION TO $650 MILLION</p></li><li><p>MIRUM PHARMACEUTICALS INC - VOLIXIBAT VISTAS STUDY IN PRIMARY SCLEROSING CHOLANGITIS <a href=\"https://laohu8.com/S/PSC\">$(PSC)$</a> TOPLINE DATA EXPECTED <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>MIRUM PHARMACEUTICALS INC - LIVMARLI EXPAND STUDY IN ADDITIONAL CHOLESTATIC PRURITUS SETTINGS TIMING ACCELERATED; TOPLINE DATA NOW EXPECTED Q4 2026</p></li><li><p>MIRUM PHARMACEUTICALS - BLUEJAY THERAPEUTICS' AZURE-1 STUDY IN HDV INTERIM DATA EXPECTED IN Q2 2026, TOPLINE PHASE 3 DATA EXPECTED IN H2 2026</p></li></ul><p>Source text: <span>ID:nBw9vnK6qa</span></p><p>Further company coverage: <span>MIRM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Mirum Pharmaceuticals Inc <span>MIRM.O</span>:</p><ul><li><p>MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUM</p></li><li><p>MIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCE</p></li><li><p>MIRUM PHARMACEUTICALS INC - 2026 EXPECTED GLOBAL NET PRODUCT SALES OF $630 MILLION TO $650 MILLION</p></li><li><p>MIRUM PHARMACEUTICALS INC - VOLIXIBAT VISTAS STUDY IN PRIMARY SCLEROSING CHOLANGITIS <a href=\"https://laohu8.com/S/PSC\">$(PSC)$</a> TOPLINE DATA EXPECTED <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>MIRUM PHARMACEUTICALS INC - LIVMARLI EXPAND STUDY IN ADDITIONAL CHOLESTATIC PRURITUS SETTINGS TIMING ACCELERATED; TOPLINE DATA NOW EXPECTED Q4 2026</p></li><li><p>MIRUM PHARMACEUTICALS - BLUEJAY THERAPEUTICS' AZURE-1 STUDY IN HDV INTERIM DATA EXPECTED IN Q2 2026, TOPLINE PHASE 3 DATA EXPECTED IN H2 2026</p></li></ul><p>Source text: <span>ID:nBw9vnK6qa</span></p><p>Further company coverage: <span>MIRM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7B5LSS:1","article_id":"2602754849","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602754849","pubTimestamp":1768224939,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline MomentumJan 12 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"简报-Mirum Pharmaceuticals公布未经审计的2025年初步业绩，展示了强劲的商业增长和管道势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":0.9},"content_text":"BRIEF-Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline MomentumJan 12 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUMMIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCEMIRUM PHARMACEUTICALS INC - 2026 EXPECTED GLOBAL NET PRODUCT SALES OF $630 MILLION TO $650 MILLIONMIRUM PHARMACEUTICALS INC - VOLIXIBAT VISTAS STUDY IN PRIMARY SCLEROSING CHOLANGITIS $(PSC)$ TOPLINE DATA EXPECTED Q2 2026MIRUM PHARMACEUTICALS INC - LIVMARLI EXPAND STUDY IN ADDITIONAL CHOLESTATIC PRURITUS SETTINGS TIMING ACCELERATED; TOPLINE DATA NOW EXPECTED Q4 2026MIRUM PHARMACEUTICALS - BLUEJAY THERAPEUTICS' AZURE-1 STUDY IN HDV INTERIM DATA EXPECTED IN Q2 2026, TOPLINE PHASE 3 DATA EXPECTED IN H2 2026Source text: ID:nBw9vnK6qaFurther company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602754849","isCrawlerRequest":true}